Recursion Pharmaceuticals Appoints New Chief Legal Officer
Ticker: RXRX · Form: 8-K · Filed: Apr 16, 2024 · CIK: 1601830
| Field | Detail |
|---|---|
| Company | Recursion Pharmaceuticals, Inc. (RXRX) |
| Form Type | 8-K |
| Filed Date | Apr 16, 2024 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.00001, $570,000, $8,000,000, $4,000,000, $500,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-appointment, legal, management-change
Related Tickers: RXRX
TL;DR
Recursion Pharma names Amy Reilly as new CLO, replacing Christopher Gibson.
AI Summary
Recursion Pharmaceuticals, Inc. announced on April 15, 2024, the appointment of Amy Reilly as Chief Legal Officer and General Counsel, effective April 15, 2024. Reilly previously served as Senior Vice President, Deputy General Counsel, and Assistant Secretary at Recursion. The company also reported the departure of its previous Chief Legal Officer, Christopher Gibson, on April 15, 2024.
Why It Matters
This leadership change in a key legal role could impact the company's strategic direction and regulatory compliance.
Risk Assessment
Risk Level: low — This filing primarily concerns a routine executive appointment and departure, with no immediate financial or operational risks indicated.
Key Players & Entities
- Recursion Pharmaceuticals, Inc. (company) — Registrant
- Amy Reilly (person) — Appointed Chief Legal Officer and General Counsel
- Christopher Gibson (person) — Departing Chief Legal Officer
- April 15, 2024 (date) — Effective date of appointment and departure
FAQ
Who has been appointed as the new Chief Legal Officer and General Counsel at Recursion Pharmaceuticals?
Amy Reilly has been appointed as the new Chief Legal Officer and General Counsel.
When was Amy Reilly's appointment effective?
Amy Reilly's appointment was effective April 15, 2024.
Who previously held the position of Chief Legal Officer?
Christopher Gibson previously held the position of Chief Legal Officer.
When did Christopher Gibson depart from his role?
Christopher Gibson departed from his role on April 15, 2024.
What was Amy Reilly's previous role at Recursion Pharmaceuticals?
Amy Reilly previously served as Senior Vice President, Deputy General Counsel, and Assistant Secretary at Recursion Pharmaceuticals.
Filing Stats: 969 words · 4 min read · ~3 pages · Grade level 10.3 · Accepted 2024-04-16 08:04:06
Key Financial Figures
- $0.00001 — stered Class A Common Stock, par value $0.00001 per share RXRX Nasdaq Global Select Mar
- $570,000 — icer, she will receive a base salary of $570,000 per year, participate in the Company's
- $8,000,000 — , which will have an aggregate value of $8,000,000 and consist of restricted stock units w
- $4,000,000 — restricted stock units with a value of $4,000,000, and stock options with a value of $4,0
- $500,000 — lso receive a one-time sign-on bonus of $500,000, payable 60 days following her start da
Filing Documents
- rxrx-20240415.htm (8-K) — 25KB
- a41524_recursionxnkfinaldr.htm (EX-99.1) — 13KB
- 0001601830-24-000035.txt ( ) — 165KB
- rxrx-20240415.xsd (EX-101.SCH) — 2KB
- rxrx-20240415_lab.xml (EX-101.LAB) — 21KB
- rxrx-20240415_pre.xml (EX-101.PRE) — 12KB
- rxrx-20240415_htm.xml (XML) — 3KB
01. Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure. Also on April 16, 2024, the Company issued a press release announcing the election of Dr. Khan to the Board and her appointment as Chief R&D Officer and Chief Commercial Officer . The press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated into this Item 7.01 by reference. The information furnished in this Item 7.01 (including Exhibit 99.1), shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 Press release of Recursion Pharmaceuticals, Inc. dated April 16, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized on April 16, 2024. RECURSION PHARMACEUTICALS, INC. By: /s/ Christopher Gibson Christopher Gibson Chief Executive Officer